Based in Cambridge, UK, Kymab, a Sanofi company, is developing novel human antibody-based therapies in a broad range of indications. Our unique platforms generate a vast repertoire of fully-human, species cross-reactive and affinity-matured antibodies against challenging targets.
With investment totalling $280m, we are using our antibody platforms to realise new opportunities in therapeutic antibodies and vaccine development.
From the Wellcome Trust Sanger Institute’s first spin-out to a leading therapeutic antibody company.Learn more
Our vision is to be a global biopharmaceutical company, driving the development of therapeutic human antibodies.Learn more
We work in partnerships, enhancing each other’s complementary skills to rapidly discover and test validated lead prospects.Learn more
Led by a team with world-class antibody development experience, we recruit key people to all parts of Kymab with proven skills in genetics, genomics, clinical medicine, drug development, antibody therapeutics, disease studies, business development and financial control.
Kymab Group Ltd: The Bennet Building (B930), Babraham Research Campus, Cambridge, United Kingdom, CB22 3AT. Registered in England. Company registration number 10414057.
Kymab has one of the most comprehensive transgenic technologies.